Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 154 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Baseline Clear all
Not listed No phase listed Observational

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

NCT03052075
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Retrospective Data Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Phase 4 Interventional

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

NCT00616694
View directory record Official record
Conditions
Osteoporosis
Interventions
Actonel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 85 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Not applicable Interventional

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002369
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 24, 2026, 8:13 PM EDT
Recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077
View directory record Official record
Conditions
Angiokeratomas
Interventions
PTX-022
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Sherman Oaks, California • Dawsonville, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

NCT00394277
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 24, 2026, 8:13 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism

NCT00144404
View directory record Official record
Conditions
Panhypopituitarism
Interventions
Not listed
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 24, 2026, 8:13 PM EDT
Withdrawn Not applicable Interventional

HRIM vs Mucosal Impedance in GERD Participants

NCT02812407
View directory record Official record
Conditions
Gastro-esophageal Reflux Disease (GERD)
Interventions
Mucosal Impedance
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 24, 2026, 8:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Baseline ACL Injury Risk Screening and Normative Data

NCT06635668
View directory record Official record
Conditions
ACL Injury, Anterior Cruciate Ligament Injuries, Musculoskeletal Injury
Interventions
Not listed
Lead sponsor
Sanford Health
Other
Eligibility
10 Years to 65 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2033
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Withdrawn No phase listed Observational

Starling/CRRT Observational Study

NCT05729048
View directory record Official record
Conditions
Hemodynamic Monitoring
Interventions
Starling
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 24, 2026, 8:13 PM EDT
Completed No phase listed Observational

Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients

NCT01470183
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 24, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

NCT04628481
View directory record Official record
Conditions
Recent Onset type1 Diabetes
Interventions
Ladarixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
14 Years to 45 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed No phase listed Observational

Baseline Vitamin D Deficiency and COVID-19 Disease Severity

NCT04628000
View directory record Official record
Conditions
Vitamin D Deficiency, Covid19
Interventions
Vitamin D
Other
Lead sponsor
Parkview Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pueblo, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 24, 2026, 8:13 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992
View directory record Official record
Conditions
Tumor Hyperinsulinism (Tumor HI)
Interventions
Ersodetug
Drug
Lead sponsor
Rezolute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Different Carbohydrate Feedings on a Hydrogen Breath Curve and Self-reported Gastrointestinal Complaints

NCT06648967
View directory record Official record
Conditions
Quality of Life
Interventions
Supplementation with a multi-ingredient whey supplement
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Clinical Time and Temporal Dynamics Study (CLIN-TIME)

NCT07812831
View directory record Official record
Conditions
Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests, Telemedicine, Time of Death, Time Perception, Time Reaction, Time Efficiency, Time Management, Population, Population Groups, Epidemic Disease, Pandemic, Sex Behavior, Sex Characteristics, Sex Hormone, Cardio-pulmonary, Surgical, Drugs of Abuse, Health Risks, Clinical Outcomes
Interventions
No Study-Assigned Intervention
Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2076
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label Trial of Tocilizumab in Schizophrenia

NCT01696929
View directory record Official record
Conditions
Schizophrenia
Interventions
Tocilizumab
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 24, 2026, 8:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409
View directory record Official record
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed No phase listed Observational Results available

Safety and Feasibility of Prima-Temp Thermometer Patch

NCT01587014
View directory record Official record
Conditions
Erythema, Edema, Papules White, Eruption
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 24, 2026, 8:13 PM EDT
Not listed No phase listed Observational

A Study to Prospectively Assess Disease Progression in Male Children With X-ALD

NCT03278899
View directory record Official record
Conditions
X-Linked Adrenoleukodystrophy
Interventions
Not listed
Lead sponsor
NeuroVia, Inc.
Industry
Eligibility
2 Years to 13 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inclusion Appeal Videos and Intent to Register for Pediatric Clinical Trials

NCT06138145
View directory record Official record
Conditions
Patient Participation, Pediatric ALL
Interventions
Video, Survey
Other · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 24, 2026, 8:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 24, 2026, 8:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer

NCT06326216
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 24, 2026, 8:13 PM EDT
Active, not recruiting Not applicable Interventional

Fully Closed Loop At Home (FCL@Home)

NCT06041971
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET system
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 24, 2026, 8:13 PM EDT